*Bristol Myers Squibb: In Legacy Portfolio, Revenue Growth Was Primarily Driven by Eliquis in 3Q, Partially Offset by Expected Continued Generic Impacts Across Remainder of Portfolio >BMY

Dow Jones · 4d ago

Please log in to view news